_256_384.jpg)
Drug Approval | April 14, 2024
Granules India’s Unit V facility in Visakhapatnam completes USFDA inspection with zero 483 observations
This facility manufactures APIs & formulations of oncology and non-oncology products.
This facility manufactures APIs & formulations of oncology and non-oncology products.
Granules India has reported total income of Rs. 1156.23 crores during the period ended December 31, 2023
Sales in the US region grew well, partially offset by the decline in the LATAM and European regions
API, PFI, and Finished dosages contribute 30%, 15%, and 55% of revenue from operations respectively for Q1FY24
The zero-observation outcome reflects the company's robust quality management systems and commitment to excellence in its operations.
The facility is over 79,000 square feet and is equipped with packaging lines
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
He has over 29 years of experience in the field of manufacturing, R&D, business and customer service management
Sucharita brings with her a rich and varied experience of two decades in Information Technology and Financial Services
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)